Liver drug study seeks to understand how body processes medication in scarred livers
NCT ID NCT05045482
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This study looks at how the drug Saroglitazar is processed in people with mild, moderate, or severe liver scarring (cirrhosis) caused by cholestatic liver disease. About 30 adults will take the drug once daily for 28 days. The goal is to measure drug levels in the blood and check for side effects, comparing results to people with healthy livers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLESTATIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zydus US002
RECRUITINGIndianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can everyday drugs shield the liver from Cirrhosis's worst threats?
- Liver health and drug processing: a closer look at casdatifan
- Could a yellow tinge predict dangerous hospital infections?
- Muscle quality on MRI may foretell liver transplant success
- Melatonin may ease sleep and brain fog in liver disease — a trial puts it to the test
- Heart scans could uncover silent damage in liver patients awaiting transplant